Cofa apha ukuba le ngxelo yakho!

I-Oral Contraceptive ngoku Ifumana imvume

Ibhalwe ngu U-Linda S. Hohnholz

I-Mayne Pharma Group Limited kunye ne-Mithra Pharmaceuticals, i-SA (i-Euronext Brussels: i-MITRA) ibhengeze i-Therapeutic Goods Administration (TGA) ivume inoveli edibeneyo yokuthintela ukukhulelwa ngomlomo i-NEXTSTELLIS® (14.2 mg ye-esttrol kunye ne-3 mg drospirenone tablets). UMayne Pharma ulindele ukuqaliswa kwentengiso kwe-NEXTSTELLIS phakathi ku-2022 exhaswa yimfundo yentengiso yezempilo yezempilo ukusukela ngoJanuwari 2022.

Print Friendly, PDF & Email

Iphuhliswe yi-Mithra Pharmaceuticals, i-NEXTSTELLIS yipilisi yokuqala yokuthintela ukukhulelwa equlethe i-estrogen entsha enempembelelo ephantsi - estetrol (E4) kunye neprogestin eqinisekisiweyo - i-drospirenone (DRSP). I-E4 yi-estrogen yendalo eyenziwa ngumzimba womntu ngexesha lokukhulelwa, ngoku iphuma kumthombo wesityalo. Iqulethe iqumrhu elitsha lemichiza (NCE), i-NEXTSTELLIS iya kufumana iminyaka emi-5 yobubodwa bemarike. 

Imakethi yase-Australia yocwangciso-ntsapho ixabisa i-A$125 yezigidi kunye ne-short-acting edibeneyo (i-estrogen kunye ne-progestin) yentengiso yocwangciso lomlomo yomlomo exabisa ngaphezu kwe-A$65 yezigidi[1].

I-CEO kaMayne Pharma uMnumzana Scott Richards uthe: “Siyavuya ukwazisa i-NEXTSTELLIS kwimarike yase-Australia. Sele iyiminyaka eli-10 ukusukela oko abasetyhini baseOstreliya benencindi yencindi yehomoni entsha ekufuneka beyiqwalasele nogqirha wabo. I-NEXTSTELLIS inikezela ngepilisi esebenzayo, ekhuselekileyo kunye nokunyamezela kakuhle kunye nokulawula umjikelezo obalaseleyo kwaye ibonise impembelelo ephantsi kwiindawo ezithile zomzimba. IMayne Pharma izibophelele kwimpilo yabasetyhini kwaye isungula iimveliso ezintsha ukuhlangabezana neemfuno zabasetyhini baseOstreliya nabaseMelika. ”

Ugqirha weMpilo yezeSondo, uGqr Terri Foran, uthe: “Izithinteli zokukhulelwa ezidityanisiweyo ziyaqhubeka nokuba yeyona ndlela isetyenziswa kakhulu yokulawulwa kokuzalwa kwehomoni e-Australia kwaye wonke ugqirha uyazi ukuba owasetyhini ngamnye uphendula ngokwahlukileyo kwiihomoni zocwangciso. Yiyo loo nto kubaluleke kakhulu ukuba sibe noluhlu lweendlela zokuthintela ukukhulelwa ukuze sikwazi ukwenza ukhetho lomntu ngamnye. Namhlanje sinoluhlu olubanzi lweeprogestins ezikhoyo, kodwa ukhetho lwe-estrogen lukhawulelwe kwi-ethinylestradiol okanye i-estradiol. Ukuba nenye i-estrogen, i-estetrol (E4), kuvula ithuba lokuba amabhinqa amaninzi akwazi ukufumana indibaniselwano ebafaneleyo. Uphando lubonisa ukuba i-esterotrol ikhetha ngakumbi kwimpembelelo yayo kwiithishu ezahlukeneyo ezamkela iihomoni kumzimba wesetyhini. Ngelixa ineziphumo ezinqwenelekayo kwinkqubo yelungu lobufazi eyimfuneko ekuthinteleni ukukhulelwa okusebenzayo okudityanisiweyo, kubonakala ngathi kunempembelelo encinci enokubakho kwisibindi kunye nebele.

Ingqonyela kaMithra uMnumzana Leon Van Rompay uthe: “Emva kwe-US, Canada kunye ne-Europe, siyakuvuyela ukufumana imvume eyongezelelekileyo yesicwangcisi sethu esiqalwayo, esiqinisekisa ukusungulwa korhwebo kwilizwekazi lesithathu. Le mvume yesine inkulu efunyenwe kulo nyaka, ihambelana ngokugqibeleleyo neshedyuli yethu, esivumela ukuba sifikelele ngaphezu kwama-80% ommandla ekujoliswe kuwo. Oku kubonisa ngakumbi ubuchule obuqinileyo bamaqela ethu kunye nokomelela kwentsebenziswano yethu noMayne Pharma, okwenza ukuba ukuqaliswa kwentengiso kwe-NEXTSTELLIS kube yeyona nto iphambili.

Print Friendly, PDF & Email

Malunga nombhali

U-Linda S. Hohnholz

U-Linda Hohnholz ubengumhleli oyintloko eTurboNews iminyaka emininzi.
Uyakuthanda ukubhala kwaye unika ingqalelo kwiinkcukacha.
Ukwaphetheyo wonke umxholo wepremiyamu kunye nokukhutshwa kweendaba.

Shiya Comment